Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HCmed Innovations CoTPE:6934 +1.53%11 EV-to-EBITDA is -24.64 as of Aug. 25, 2026. GuruFocus rates TPE:6934 with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 516 Medical Devices & Instruments companies, HCmed Innovations Co ranks worse than 193798.26% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, HCmed Innovations Co's enterprise value is NT$2,321.7 Mil.
HCmed Innovations Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-94.2 Mil. Therefore, HCmed Innovations Co's EV-to-EBITDA for today is -24.64.
The historical rank and industry rank for HCmed Innovations Co's EV-to-EBITDA or its related term are showing as below:
TPE:6934'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -239.65 Med: -30.1 Max: 55.77
Current: -21.53
During the past 5 years, the highest EV-to-EBITDA of HCmed Innovations Co was 55.77. The lowest was -239.65. And the median was -30.10.
TPE:6934's EV-to-EBITDA is ranked worse than 100% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.67
vs TPE:6934: -21.53
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
HCmed Innovations Co (TPE:6934) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
HCmed Innovations Co's PE Ratio (TTM) for today is calculated as:
HCmed Innovations Co's share price for today is NT$73.10.
HCmed Innovations Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-3.540.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for HCmed Innovations Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6934 vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, HCmed Innovations Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCmed Innovations Co EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HCmed Innovations Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where HCmed Innovations Co's EV-to-EBITDA falls into.
HCmed Innovations Co's current Enterprise Value is NT$2,321.7 Mil.
HCmed Innovations Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-94.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCmed Innovations Co (TPE:6934) has a EV-to-EBITDA of -24.64 as of Aug. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on HCmed Innovations Co. According to the industry distribution chart, HCmed Innovations Co ranks #999999 out of 516 companies in the Medical Devices & Instruments industry.
Is HCmed Innovations Co's EV-to-EBITDA too high?
HCmed Innovations Co's current EV-to-EBITDA is -24.64. Based on the distribution chart, HCmed Innovations Co ranks #999999 out of 516 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, HCmed Innovations Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does HCmed Innovations Co's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HCmed Innovations Co ranks #999999 out of 516 companies for EV-to-EBITDA. This places HCmed Innovations Co in the lower half of its industry. The industry median EV-to-EBITDA is 14.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.67, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on HCmed Innovations Co. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCmed Innovations Co's current EV-to-EBITDA is -24.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCmed Innovations Co stock overvalued right now?
HCmed Innovations Co (TPE:6934) has a current EV-to-EBITDA of -24.64. The current EV-to-EBITDA is -24.64. HCmed Innovations Co's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For HCmed Innovations Co (TPE:6934), the current EV-to-EBITDA is -24.64 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HCmed Innovations Co Ltd is engaged in designing, developing, manufacturing and selling drug delivery system. It is focused on inhalation therapy to create integrated drug nebulizer combination products featuring nebulization therapeutic drugs that include small molecule synthetics and large molecule biologics, as either solutions, suspensions, and even difficult-to-deliver high viscosity drugs. Its product includes Pulmogine. Geographically, the company operates in America, Europe, Asian and African regions.
11GF Score
Get the complete analysis for TPE:6934
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6934 has been successfully added to your 
